Presentations at AACR 2026 will showcase fragmentomics-based technology for detecting therapeutic markers and providing prognostic insight.

Researchers will present new data on ExpressCT liquid biopsy technology at the American Association for Cancer Research (AACR) Annual Meeting 2026 in San Diego. The presentations focus on using fragmentomics to infer gene expression from cell-free DNA (cfDNA), a method that expands the application of liquid biopsy testing beyond standard mutation profiling.

The technology is compatible with multiple assay formats, including whole genome sequencing (WGS), established gene panels, and custom hybrid-capture panels. According to GeneCentric, the data demonstrate that fragmentomics can provide prognostic insight and detect established therapeutic markers, such as ER and other gene signatures.

“Our 2026 AACR presentations will showcase the significant progress we’ve made in advancing our ExpressCT liquid biopsy technology,” says Michael Milburn, PhD, president and chief executive officer of GeneCentric, in a release. “Our data show that fragmentomics can provide prognostic insight, detect established therapeutic markers such as ER and other gene signatures, and demonstrate a path extending liquid biopsy utility beyond mutation profiling.”

Poster Sessions and Technical Applications

The data will be presented across three poster sessions on April 21. One study involves fragmentomic analysis of cfDNA WGS at regulatory regions to generate gene-level expression-like traits for subtype analysis in breast cancer.

Another presentation details a method for combining gene expression and mutation profiling into a single cfDNA assay. This is achieved by adding a custom hybrid capture panel targeting gene regulatory regions to a commercial cancer gene profiling panel.

A third poster focuses on metastatic breast cancer, using fragmentomics analysis of targeted hybrid capture next-generation sequencing (NGS) data to develop a prognostic model.

Expanding Liquid Biopsy Utility

Beyond the posters, presentations will cover the inference of gene expression from cfDNA and the development of assays for tumor phenotyping. The ExpressCT technology uses information embedded in cfDNA to infer gene expression, aiming to identify biomarkers that may indicate potential oncology treatment benefits.

The company currently provides its technology through strategic collaborations with biopharmaceutical and diagnostics companies. These applications span various phases, including preclinical testing, clinical drug development, and commercialization lifecycle phases.

ID 176719290 © Franky44 | Dreamstime.com

Related Reading: